SSI exemption turnover inclusion and limitation: disclosed clearances barred the extended period despite a sustainable duty demand on merits.

For SSI exemption under Notification No. 8/2003, the value of exempted clearances of SHASTROKTA medicines had to be included in aggregate turnover because all clearances counted unless specifically excluded; the substantive duty demand was therefore sustainable on merits. However, the assessee had disclosed the relevant clearance values to the Department, including patent and proprietary medicines as well as SHASTROKTA medicines, so suppression, misdeclaration, or fraudulent intent to evade duty was not established. The extended period under Section 11A of the Central Excise Act, 1944 was therefore not invokable, the demand was time-barred, and the order was set aside with consequential relief.

---

---

Issues: (i) Whether, for availing SSI exemption under Notification No. 8/2003, the value of exempted clearances of SHASTROKTA medicines was required to be included in the aggregate turnover. (ii) Whether the extended period under Section 11A of the Central Excise Act, 1944 was invokable in the facts of the case.

Issue (i): Whether, for availing SSI exemption under Notification No. 8/2003, the value of exempted clearances of SHASTROKTA medicines was required to be included in the aggregate turnover.

Analysis: The notification required inclusion of all clearances in the aggregate value of turnover except those specifically excluded under para 3A. The appellant had not included the value of SHASTROKTA medicines while computing the turnover for SSI eligibility, although those clearances formed part of the excisable goods cleared for home consumption. The declaration that the appellant acted under a bona fide belief did not alter the express requirement of the notification.

Conclusion: The value of SHASTROKTA medicines was required to be included in the aggregate turnover and the duty demand was legally sustainable on merits.

Issue (ii): Whether the extended period under Section 11A of the Central Excise Act, 1944 was invokable in the facts of the case.

Analysis: The appellant had disclosed the relevant clearance values in letters filed with the Department, including the values of both patent and proprietary medicines and SHASTROKTA medicines. On those facts, the ingredients of suppression, misdeclaration, or fraudulent intent necessary for invocation of the extended limitation period were not established. The absence of intent to evade duty barred recourse to the extended period.

Conclusion: The extended period under Section 11A was not invokable and the demand was time-barred.

Final Conclusion: Although the demand was sustainable on the substantive turnover issue, it failed on limitation, and the impugned order was set aside with consequential relief to the appellant.

Ratio Decidendi: Where the assessee has made full disclosure of clearance values, the extended period of limitation cannot be invoked in the absence of suppression, misdeclaration, or fraudulent intent to evade duty, even if the demand is otherwise sustainable on merits.

---